PubMed

Immunologic aspects of human proinsulin therapy.

Fineberg SE, Rathbun MJ, Hufferd S, Fineberg NS, Spradlin CT, Galloway JA, Frank BH.

Diabetes. 1988 Mar;37(3):276-80.PMID: 3286327 [PubMed - indexed for MEDLINE]Related articles

Biosynthetic human proinsulin. Review of chemistry, in vitro and in vivo receptor binding, animal and human pharmacology studies, and clinical trial experience.

Galloway JA, Hooper SA, Spradlin CT, Howey DC, Frank BH, Bowsher RR, Anderson JH.

Diabetes Care. 1992 May;15(5):666-92. Review.PMID: 1516487 [PubMed - indexed for MEDLINE]Related articles

Proinsulin autoantibodies are more closely associated with type 1 (insulin-dependent) diabetes mellitus than insulin autoantibodies.

Böhmer K, Keilacker H, Kuglin B, Hübinger A, Bertrams J, Gries FA, Kolb H.

Diabetologia. 1991 Nov;34(11):830-4.PMID: 1769442 [PubMed - indexed for MEDLINE]Related articles

The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.

Anderson OO.

Acta Endocrinol (Copenh). 1975 Apr;78(4):723-35.PMID: 1173962 [PubMed - indexed for MEDLINE]Related articles

Effects of biosynthetic human proinsulin on plasma lipids in type 2 diabetes mellitus.

Drexel H, Hopferwieser T, Braunsteiner H, Patsch JR.

Klin Wochenschr. 1988 Dec 1;66(23):1171-4.PMID: 3062266 [PubMed - indexed for MEDLINE]Related articles

Immunogenicity of highly purified bovine insulin: a comparison with conventional bovine and highly purified human insulins.

Wilson RM, Douglas CA, Tattersall RB, Reeves WG.

Diabetologia. 1985 Sep;28(9):667-70.PMID: 3905477 [PubMed - indexed for MEDLINE]Related articles

Immunologic effects of insulin lispro [Lys (B28), Pro (B29) human insulin] in IDDM and NIDDM patients previously treated with insulin.

Fineberg NS, Fineberg SE, Anderson JH, Birkett MA, Gibson RG, Hufferd S.

Diabetes. 1996 Dec;45(12):1750-4.PMID: 8922361 [PubMed - indexed for MEDLINE]Related articles

Receptor binding studies and clinical effects of human insulin (recombinant DNA): studies in patients with newly diagnosed type i diabetes, type II diabetes, insulin resistance (type A and type B), insulin antibodies, insulin allergy, and "brittle" diabetes.

Schlüter KJ, Kerp L.

Diabetes Care. 1982 Nov-Dec;5 Suppl 2:152-60.PMID: 6765528 [PubMed - indexed for MEDLINE]Related articles

Comparative study of insulin antibodies in diabetic patients with primary insulin-dependence (type I) and secondary insulin-dependence (type II).

Ionescu-Tîrgovişte C, Mirodon Z, Cheţa D, Sântu E, Simionescu M, Nicolau A, Mincu I.

Med Interne. 1989 Oct-Dec;27(4):303-11.PMID: 2694321 [PubMed - indexed for MEDLINE]Related articles

Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial.

Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A.

J Clin Endocrinol Metab. 2005 Jun;90(6):3287-94. Epub 2005 Mar 1.PMID: 15741258 [PubMed - indexed for MEDLINE]Related articlesFree article

Development of IgE antibodies to human (recombinant DNA), porcine, and bovine insulins in diabetic subjects.

Fireman P, Fineberg SE, Galloway JA.

Diabetes Care. 1982 Nov-Dec;5 Suppl 2:119-25.PMID: 6765521 [PubMed - indexed for MEDLINE]Related articles

Clinical investigations into the modification of the effect of endogenous and exogenous insulin by human proinsulin in type II and type I diabetics.

Bellenberg S, Schröder KE, Schlüter KJ, Bottermann P, Zilker T, Gray P.

Horm Metab Res Suppl. 1988;18:77-83.PMID: 3056817 [PubMed - indexed for MEDLINE]Related articles

Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.

Carroll PV, Umpleby M, Alexander EL, Egel VA, Callison KV, Sönksen PH, Russell-Jones DL.

Clin Endocrinol (Oxf). 1998 Dec;49(6):739-46.PMID: 10209561 [PubMed - indexed for MEDLINE]Related articles

Proinsulin level in diabetes mellitus measured by a new immunochemiluminometric assay.

Wu TJ, Lin CL, Taylor RL, Kao PC.

Ann Clin Lab Sci. 1995 Nov-Dec;25(6):467-74.PMID: 8572555 [PubMed - indexed for MEDLINE]Related articles

Decrease of antibodies to insulin, proinsulin and contaminating hormones after changing treatment from conventional beef to purified pork insulin.

Kurtz AB, Matthews JA, Mustaffa BE, Daggett PR, Nabarro JD.

Diabetologia. 1980;18(2):147-50.PMID: 6988274 [PubMed - indexed for MEDLINE]Related articles

Clinical experience with human proinsulin in eighteen patients with type I and type II diabetes mellitus.

Thomas VA, Lamberton RP, Krauss DS, Kahn CB.

R I Med J. 1991 Oct;74(10):463-8. No abstract available. PMID: 1957115 [PubMed - indexed for MEDLINE]Related articles

Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.

Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.

Clin Ther. 2004 May;26(5):724-36.PMID: 15220016 [PubMed - indexed for MEDLINE]Related articles

Growth hormone-binding protein related immunoreactivity is regulated by the degree of insulinopenia in diabetes mellitus.

Kratzsch J, Keliner K, Zilkens T, Schmidt-Gayk H, Selisko T, Scholz GH.

Clin Endocrinol (Oxf). 1996 Jun;44(6):673-8.PMID: 8759179 [PubMed - indexed for MEDLINE]Related articles

Effect of long-term exposure to insulin lispro on the induction of antibody response in patients with type 1 or type 2 diabetes.

Fineberg SE, Huang J, Brunelle R, Gulliya KS, Anderson JH Jr.

Diabetes Care. 2003 Jan;26(1):89-96.PMID: 12502663 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of species of origin, purification levels, and formulation on insulin immunogenicity.

Fineberg SE, Galloway JA, Fineberg NS, Goldman J.

Diabetes. 1983 Jul;32(7):592-9.PMID: 6345238 [PubMed - indexed for MEDLINE]Related articles